» Articles » PMID: 39361729

Omicron-specific Ultra-potent SARS-CoV-2 Neutralizing Antibodies Targeting the N1/N2 Loop of Spike N-terminal Domain

Abstract

A multitude of functional mutations continue to emerge on the N-terminal domain (NTD) of the spike protein in SARS-CoV-2 Omicron subvariants. Understanding the immunogenicity of Omicron NTD and the properties of antibodies elicited by it is crucial for comprehending the impact of NTD mutations on viral fitness and guiding vaccine design. In this study, we find that most of NTD-targeting antibodies isolated from individuals with BA.5/BF.7 breakthrough infection (BTI) are ancestral (wild-type or WT)-reactive and non-neutralizing. Surprisingly, we identified five ultra-potent neutralizing antibodies (NAbs) that can only bind to Omicron but not WT NTD. Structural analysis revealed that they bind to a unique epitope on the N1/N2 loop of NTD and interact with the receptor-binding domain (RBD) via the light chain. These Omicron-specific NAbs achieve neutralization through ACE2 competition and blockage of ACE2-mediated S1 shedding. However, BA.2.86 and BA.2.87.1, which carry insertions or deletions on the N1/N2 loop, can evade these antibodies. Together, we provided a detailed map of the NTD-targeting antibody repertoire in the post-Omicron era, demonstrating their vulnerability to NTD mutations enabled by its evolutionary flexibility, despite their potent neutralization. These results revealed the function of the indels in the NTD of BA.2.86/JN.1 sublineage in evading neutralizing antibodies and highlighted the importance of considering the immunogenicity of NTD in vaccine design.

Citing Articles

SARS-CoV-2 neutralizing antibody specificities differ dramatically between recently infected infants and immune-imprinted individuals.

Dadonaite B, Burrell A, Logue J, Chu H, Payne D, Haslam D bioRxiv. 2025; .

PMID: 39896663 PMC: 11785066. DOI: 10.1101/2025.01.17.633612.


Structural Immunology of SARS-CoV-2.

Yuan M, Wilson I Immunol Rev. 2024; 329(1):e13431.

PMID: 39731211 PMC: 11727448. DOI: 10.1111/imr.13431.

References
1.
Yang S, Yu Y, Jian F, Yisimayi A, Song W, Liu J . Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1. Emerg Microbes Infect. 2024; 13(1):2343909. PMC: 11073414. DOI: 10.1080/22221751.2024.2343909. View

2.
Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L . BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022; 608(7923):593-602. PMC: 9385493. DOI: 10.1038/s41586-022-04980-y. View

3.
Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, Rapp M . Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021; 29(5):819-833.e7. PMC: 7953435. DOI: 10.1016/j.chom.2021.03.005. View

4.
Meng B, Kemp S, Papa G, Datir R, Ferreira I, Marelli S . Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 2021; 35(13):109292. PMC: 8185188. DOI: 10.1016/j.celrep.2021.109292. View

5.
Cao Y, Song W, Wang L, Liu P, Yue C, Jian F . Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. Cell Host Microbe. 2022; 30(11):1527-1539.e5. PMC: 9531665. DOI: 10.1016/j.chom.2022.09.018. View